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PHOSPHATE DIABETES
A REVIEW
GEOFFREY FALKSON, M.B. Ch.B* .\ND BOY FRAME,

M.D.*

Phosphate diabetes is the term proposed by Fanconi for the clinical entity otherwise known as vitamin D resistant rickets.^'' Most of the information regarding this
condition has been gained by the study of individual cases. Its infrequent occurrence
has prevented a cumulative experience by any one group. Larger series have been
studied for the most part when the disease presented a familial incidence.' The most
complete clinical studies have been performed by Swoboda," who reports 11 cases, and
by Tobler working with Prader and Taillard,^-' who report 16 cases. This paper is a
review of data obtained from approximately 150 of the more detailed case reports in
the world literature and was prompted by the study at this hospital of a patient with
severe osteomalacia due to phosphate diabetes.'
Since the description of the famflial occurrence of tardy rickets by Baagoe' and
of similar cases resistant to the usual dosage of vitamin D by Jampolis and Londe,'
interest has been stimulated in rickets and osteomalacia not complicated by demonstrable renal disease or intestinal mat-absorption, yet resistant to average doses of
vitamin D. In 1937, Albright demonstrated in phosphate diabetes the abflity of
vitamin D in massive doses to overcome what he referred to as an intrinsic resistance
to vitamin D.'° It soon became apparent that despite the cflnical remission achieved
with massive vitamin D therapy, the fasting serum inorganic phosphorus level remained
depressed in many instances, suggesting that the disease was not due to vflamin D
resistance alone. Robinson, Harris and McCune postulated that primary renal hyperphosphaturia, as demonstrated by the decreased tubular reabsorption of phosphorus,
may explain the pathogenesis of the disorder." This concept was opposed to Albright's
stand that the hypophosphatemia in phosphate diabetes resulted at least in part from
secondary hyperparathyroidism.Either concept may account for the reduced tubular
reabsorption of phosphorus and depressed serum inorganic phosphorus found in
phosphate diabetes.
Fanconi defined phosphate diabetes as including all cases of osteomalacia without
other renal lesions or intestinal mal-absorption and having the following characteristics:'
1. Familial, usually with a dominant genetic pattern. 2. Chronic absolute vitamin D
resistant hypophosphatemia. 3. Elevated alkaline phosphatase before vitamin D therapy.
4. Normal or hyperphosphaturia, high phosphate clearance, and only minimal increase
in phosphate excretion during the Ellsworth-Howard phosphaturia test. 5. Pronounced
hypocalciuria. 6. Appearance after the first year. 7. Retarded growth with a sturdy
body configuration.
Dent considers that phosphate diabetes is a unifactoral renal tubular defect leading
to hyperphosphaturia and osteomalacia." A multi-factoral tubule defect when present
would then result in the more complicated conditions of renal tubulur acidosis and the
Fanconi syndrome, which may also be associated with osteomalacia.
'Department of Medicine.
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REVIEW OF CASES.
Few cases of phosphate diabetes reported in the literature have been sufficiently
investigated to completely fulfill Fanconi's criteria. We have chosen patients for
review in whom, as far as can be determined, there was no question concerning the
diagnosis of rickets or osteomalacia from a clinical and biochemical standpoint. Cases
with steatorrhea or evidence of a more advanced renal tubular abnormality, manifested
as renal tubular acidosis or Fanconi's syndrome, were excluded. A f l cases showed
moderate or marked resistance to treatment with vitamin D. In only a few cases was
sufficient study of the urinary phosphorus excretion available to determine whether
this was above normal. Since, however, there is strong evidence that primary renal
hyperphosphaturia is the main pathogenic defect the collected cases have been grouped
under the heading, renal phosphate diabetes. We suspect that many if not all the
cases of vitamin D resistant rickets reported in the world hterature are examples of
phosphate diabetes. This may be in error since there is no absolute proof that a common
etiology is present in all cases. Of approximately 180 avaflable cases we consider the
data adequate in only 150.' 3-5.7,9-11,13-25,27,28,36,37,50-84 ^ statistical analysis would have
little meaning because of variation in method of reporting the clinical data; therefore
many of the conclusions in this report are derived from the study of the individual
case reports.
There is a positive family history of the disease in a large number of patients.
There are 50 families on record with more than one member affected. Pedersen' was
the first to draw attention to this clinically significant fact. Mitchefl and Mitchell"
on the basis of a family history involving five generations were able to postulate that
the disease is due to a single dominant autosomal gene of variable expressiveness.
The youngest case of phosphate diabetes on record was an infant of 7 months
described by Harrison." Since the patient's mother had an inactive form of the disease,
its presence in the infant was suspected from birth. The majority of patients with the
disease fall between the ages of I1/2 and 16 years of age. The oldest patient with
active disease at the time of diagnosis was 57 years old, and gross deformities had
been present for many years prior to the diagnosis.'' The incidence of active phosphate
diabetes is less in adults, there being on record only 12 patients in whom the disease
had its onset after the age 14. Since 60 per cent of the cases were females and 40
per cent males, there appears to be no striking sex predominance.
The clinical picture of phosphate diabetes has been described adequately in many
of the individual case reports, especially when it has occurred in childhood. A child's
first attempt to walk often calls attention to the disease since gradual convex curving
of the thighs or genu valgus may appear early. The gait may be waddling and at times
suggestive of that seen in muscular dystrophy. General weakness is sometimes present,
but true muscle hypotonia is less common than in classical deficiency rickets. The
general condition otherwise may be quite good. When the disease occurs in infancy
and childhood, there may be relatively little bone pain and tenderness despite rather
severe skeletal deformity. Of unknown significance is the association of phosphate
diabetes and a number of seemingly unrelated anomalies. These include albinism,"
mental deficiency," neurofibromatosis" and craniostenosis.^""
The serum chemistry is similar to that found in vitamin D deficiency rickets. The
serum calcium is usually normal, but occasionally slightly depressed. Among the cases
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reviewed the highest serum calcium was 11.3 and the lowest, 7.5 mgm. per cent.22.2J
The average serum calcium for the cases was 9.8 before and 10.8 mgm. per cent during
treatment. Persistent hypophosphatemia, considered one of the hallmarks of the disease,
is present in almost afl cases. The lowest serum inorganic phosphorus value reported
was 0.17 and the highest, 7.2 mgm. per cent."-" The average serum inorganic phosphorus in all cases was 2.5 before and 3.5 mgm. per cent during treatment with vflamin
D bordering on toxic levels. Considering the large number of infants and young
children in this series, we consider the value of 3.5 mgm. per cent to be lower than
normal. The alkaline phosphatase is generafly elevated, but there are documented
cases in the active phase of the disease with a normal value.' In pure phosphate diabetes
the serum electrolytes wfll be normal and the 24 hour urinary calcium depressed.
Increased amounts of glucose and amino-acids will not be present in the urine
unless there is a more extensive renal tubular defect. By definition, the term pure
phosphate diabetes would no longer apply. Dent, however, using paper chromatography, found an increase in urinary glycine excretion in patients with phosphate
diabetes resulting in what he cafls the "superglycine" spot."
Since the urinary phosphorus excretion in phosphate diabetes has received attention
only in recent years, relatively little data is available in the literature for analysis.
Further work is needed to evaluate the various factors that control excretion of phosphorus in the urine, both in terms of quantitative values and in terms of the various
phosphorus reabsorption tests. A number of authors have studied this problem in
patients with phosphate diabetes.'-'-''"'"-" Increased urinary excretion of phosphorus
has been found in a high percentage but not in all patients with the disease. However,
considering the low serum inorganic phosphorus, a normal value for urinary phosphorus
excretion may indicate ui actuality an excessive loss. In some cases of phosphate
diabetes, this excretory rate has continued even after fasting when the serum inorganic
phosphorus had fallen almost to zero."
Roentgenograms of the reported cases in childhood simulate those of florid deficiency rickets. There is generalized demineralization of bone and unusually prominent
bony trabeculae. The metaphyses of the long bones are broad and frayed, while changes
in the spine occur less frequently. The lamina dura is intact unless the bone changes
are extremely severe.
We have been particularly interested in clinicafly active phosphate diabetes as
manifested in late adolescence and adulthood. Heretofore, the greatest emphasis has
been placed on its occurrence in infancy and childhood. It cannot be said with certainty
that the adult form is the same disease or has the same pathogenesis as that found in
childhood, but many of the features are similar. As far as can be determined, the
nature of the underlying bone disease is identical. In infancy and childhood, due to
the unclosed epiphyseal discs, the picture is that of rickets, while after closure of the
discs adult osteomalacia is the result. In both instances, poorly calcified bone matrix
is the basic abnormality. Hypophosphatemia, both before and after treatment usually
occurs in adult cases as well as in childhood. When the disease begins in childhood it
frequently becomes inactive and stationary as growth ceases, but the bone deformities
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and hypophosphatemia remain into adulthood. The alkaline phosphatase in these adult
cases is frequently normal.^ We have not considered such adult cases to have active
phosphate diabetes. On the other hand, we have found reports of approximately 11
cases in which the disease had its onset during or after adolescence and which continued
in a progressive fashion until treatment was instituted. These are included in Table I .
As far as could be determined there was no definite family history of rickets or
osteomalacia in any of the cases, in contrast to the high familial incidence of the
childhood form of the disease.'-''' Bone pain, tenderness and moderate muscular
weakness, seldom complaints in children with the disease, are prominent features in adult
cases. A loss in height of 4-6 inches in adults with the disease is common. The x-ray
picture in the adult shows no metaphyseal change but pseudofractures occur often.
The latter are rare in the childhood form of the disease.
The treatment of phosphate diabetes is not entirely satisfactory. Untreated children
reach adult life with gross bony deformities and are dwarfed. There is recorded only
one patient whose disease, having begun in childhood, remained active after growth
had ceased.'' On the other hand, when the onset is in the adult there is more apt
to be steady progression. For many years treatment has consisted of massive doses of
vitamin D and calcium supplements. Since most of the cases were started on very
large doses of the vitamin as soon as the diagnosis was established, it is impossible to
determine the minimal amount necessary to produce improvement. In the cases reviewed, no clinical improvement was achieved on less than 10,000 units of vitamin
D daily, while some patients required as much as 1,500,000 units daily." A limiting
factor in such therapy has been toxicity to the vitamin, in some cases resulting in
intolerable hypercalcemia which occasionally necessitated reduction in dosage to an
ineffective level.
The use of added oral phosphorus in the treatment of phosphate diabetes has
been emphasized recently. Saville demonstrated increased calcium and phosphorus
retention in patients with the disease who were given such treatment." In another
recent case report there was striking clinical and radiologic improvement after the
addition of 2 to 3 grams of oral phosphorus daily, whereas treatment with large doses
of vitamin D and calcium alone during the previous five years had resulted in only
minimal improvement.' I f the hypothesis is correct that phosphate diabetes is at least
partly a consequence of negative phosphorus balance due to primary hyperphosphaturia,
the use of oral phosphorus supplements seems physiologicafly sound.
Many patients with phosphate diabetes have been followed in orthopedic clinics
for a number of years with the erroneous diagnosis of osteodystrophy and as a result
osteotomies were performed to correct the bony defect. I f the diagnosis of phosphate
diabetes has been correctly established and large doses of vitamin D already initiated,
this must be discontinued while the patient is undergoing various orthopedic corrections.
Otherwise, immobflization in addition to the high dose of vitamin D, may result in
dangerous hypercalcemia and nephrocalcinosis.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis of phosphate diabetes includes a variety of diseases.
Other forms of rickets and osteomalacia must be excluded. It differs from classical
247

Falkson and Frame
deficiency rickets not only in that there is resistant hypophosphatemia, family predisposition, the spontaneous occurrence at any age, and relative vitamin D resistance,
but also in that continued intensive therapy is necessary without assurance of cure.
Mal-absorption syndromes with resulting osteomalacia should be differentiated by
appropriate studies. Hypophosphatasia, a recently described syndrome simulating
rickets from the radiologic and pathologic aspect, is identified by the markedly
depressed serum and tissue alkaline phosphatase.^ The more extensive renal tubular
defects with associated osteomalacia, such as tubular acidosis and the Fanconi syndrome,
may be differentiated by the presence of systemic acidosis in the former and aminoaciduria as wefl as glucosuria in the latter. In actuality, the hyperphosphaturia in
Fanconi's syndrome might also be labeled phosphate diabetes, but there are sufficient
additional features to keep this entity separate from pure phosphate diabetes. Little
difficulty is encountered in differentiating hyperparathyroidism and osteoporosis. The
hypercalcemia and hypercalciuria in the former and the normal serum phosphorus in
the latter are usually sufficient.
Dwarfism and deformed extremities in phosphate diabetes have often resulted in
a diagnosis of osteodystrophy or chondrodystrophy. However, in these diseases the
serum calcium, phosphorus and phosphatase, are almost always normal and there is
no evidence of hyperphosphaturia. There are a number of non-rachitic varieties of
crural varus and valgus that have in the past been confused with the bony deformities
of phosphate diabetes. Many of these latter patients have had one or more osteotomies
for correction of the deformities without recognition of the underlying metabolic
defect. When Pedersen' reviewed such cases in his clinic, a surprising number of
patients with phosphate diabetes were uncovered.
PATHOGENESIS
The pathogenesis of phosphate diabetes is still to be completely elucidated. For
many years the resistance of the disease to the usual doses of vitamin D led to the
term vitamin D resistant rickets or osteomalacia. This term was strengthened by the
fact that many patients so diagnosed responded to vitamin D only in doses bordering
on toxic levels. There are several features which indicate that simple resistance to the
vitamin is not the most likely explanation for the condition.
One of the strongest arguments that more than a vitamin resistance is involved
is the repeated observation that the vitamin D required for improvement in phosphate
diabetes calls forth a different set of responses from those occuring during the treatment
of deficiency osteomalacia. Wflh a therapeutic response in the latter, one of the
early changes is a prompt elevation of the fasting serum inorganic phosphorus. This
is due to increased absorption of phosphorus from the intestine as well as to its
improved renal tubular reabsorption. This elevation of serum inorganic phosphorus
aids prompt ossification of poorly mineralized bone matrix. Enhanced absorption of
calcium is an additional factor in the accelerated ossification. It is true that excessive
doses of vflamin D used in the treatment of phosphate diabetes will also improve
intestinal absorption of calcium and phosphorus. In this instance, however, a low serum
inorganic phosphorus often persists despite the fact that radiologic studies may show
healing of the osteomalacia. The fact that vitamin D returns the serum inorganic
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phosphorus to normal in simple vitamin deficiency osteomalacia, but only infrequently
in phosphate diabetes with osteomalacia, suggests a different mechanism of action of
the vitamin in the two diseases. In the former its action may be physiological in nature,
whfle in phosphate diabetes a pharmacological action may affect ossification of bone
without affecting the internal homeostasis of phosphorus. Further biochemical differences between these two diseases entities are demonstrated by healing properties of
dihydrotachysterol in phosphate diabetes, but not in deficiency rickets." I f the same
biochemical system is at fault in deficiency osteomalacia as in phosphate diabetes
(vitamin resistant osteomalacia) these variances in response to vitamin D and dihydrotachysterol are difficult to explain. Despite the fact that in normal individuals excess
vitamin D tends to cause demineralization of bone, this action is not seen in phosphate
diabetes." This again suggest that the action of vitamin D is not physiological in the
latter condition. The relative hyperphosphaturia seen in phosphate diabetes but not in
deficiency osteomalacia also points to biochemical dissimilarities.'"' If the two conditions
were basically the same disease process, except for the wide dosage difference in
response to vitamin D, we suggest that there would not be these striking disparaties
either before or after the administration of the vitamin. Contrary to this reasoning.
Freeman and Dunsky" concluded in 1950 that with massive vitamin D therapy one
effect of vitamin D may be accentuated without a second effect being influenced and
yet, cflnical healing achieved. Harrison's concept of the involvement of two different
biochemical systems being affected at the two extremes of dosage is an interesting
consideration in this regard." It is also pertinent to ask why a resistance to vitamin D
is not apparent in the first few months of flfe if this is the only etiologic factor in
phosphate diabetes. In no case described in the literature has an allergic or hypersensitivity reaction to the vitamin been described which might acount for an acquired
resistance.
Since we believe that the disease is not simply due to a resistance to the action of
vitamin D, we prefer the term proposed by Fanconi and others of primary renal
phosphate diabetes. This implies a relative increased phosphorus excretion in the urine.
To demonstrate an absolute increase in urinary phosphorus excretion in the disease
is difficult due to the problem of controlling the many factors that regulate fls total
excretion. However, with the use of renal tubular phosphorus reabsorption tests, renal
clearance of phosphorus has been shown to be increased in a number of instances of
phosphate diabetes.'-''''''' Winberg and co-workers," on the other hand, associate this
high renal phosphorus clearance with an increasing dietary content of phosphorus and
propose that these are proportional. Thus they rejected the term phosphate diabetes and
continue to prefer the term "primary vitamin D refractory rickets". The proponents
of the existence of an increased renal phosphorus clearance in the disease suggest that
the main defect is due to either a congenflal or an acquired renal tubular defect.
Evidence of a primary tubular defect in phosphate diabetes is supported by the fact
that there are reported gradations from true phosphate diabetes to the more generally
accepted renal tubular defect found in the Fanconi syndrome. The combination of
hyperphosphaturia and amino-aciduria, as wefl as hyperphosphaturia and glucosuria,
have been reported in separate cases.'''''" This evidence suggests that the eventual
clinical manifestations depend upon the degree of renal tubular dysfunction. It has
been suggested that an enzymatic defect in the tubules may be primary in the deficient
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reabsorption of phosphorus. A decrease in the alkaline phosphatase staining reaction
in the tubules of patients with phosphate diabetes has been reported,"''''" but not
universally.' An unusual anatomical configuration of the renal tubules described as
a "swan neck configuration","^ as well as reduced alkaline phosphatase staining reaction
has been reported in the closely related but more complicated renal tubular defect
decsribed by Fanconi. Availability of renal punch biopsy should make possible further
histochemical study in a variety of renal tubular syndromes.
For a number of years Albright has explained the low serum in organic phosphorus
in phosphate diabetes partially on the basis of secondary hyperparathyroidism. It is true
that in some of the pathological studies of the parathyroid glands in the disease chief
cell hyperplasia has been present. There is no definite proof, however, that this
hyperplasia represents a hyperfunctioning state. The stimulus for secondary hyperparathyroidism has been considered to be either a high serum phosphorus or a low serum
calcium. In phosphate diabetes the former occurs rarely," and the latter is found infrequently. Even in the infant case of Harrison" where serum calcium and phosphorus
were foflowed almost from birth there was no exiciting hypocalcemia or hyperphosphatemia that might have acted as an initial stimulus for compensatory hyperparathyroidism.
The normo-phosphaturia in deficiency rickets, where secondary hyperparathyroidism
is also thought to be in action is in contrast to the frequently seen increased renal
clearance of phosphorus in phosphate diabetes. If functioning secondary hyperparathyroidism is in force in both conditions, the hyperphosphaturia only in phosphate diabetes
remains unexplained. This evidence favors a primary renal phosphrous loss as the
cause for the hyperphosphaturia in phosphate diabetes rather than secondary hyperparathyroidism.
Withdrawal of phosphorus from the skeleton and osteomalacia would be the
natural consequence of an abnormal urinary phosphorus loss unless there was replacement from a dietary source. This concept would designate the disease purely as one
of disturbed phosphorus metabolism and would relegate the importance of calcium and
vitamin D to a lesser role. I f phosphorus is withdrawn from the skeleton due to a
negative phosphorus balance, mobilization of skeletal calcium would also occur. This
does not appear in the urine since the urinary calcium is depressed in most cases. That
this mobilized calcium in phospate diabetes may be excreted into the intestines, has
received support from the report of Swann." This investigator found on balance studies
in patients with the disease that calcium excretion in the stools exceeded the intake.
Since the initial interest in phosphate diabetes many pathogenic mechanisms other
than those already discussed have been proposed. In 1932 Cockayne,' when commenting on the reported cases of resistant rickets, wondered whether these patients
were not suffering from an osseous dystrophy determined geneticafly rather than from
acquired rickets. The idea of a basic defect in osteoid tissue, possibly enzymatic in
nature causing difficulty in ossification, has since been commented upon by many
other authorities on bone metabolism. An even more generalized disturbance of
phosphorus metaboflsm at the cellular level has found some laboratory support. Sterns
and Warweg found the organic acid soluble ester phosphorus of the red blood cefls
to be increased despite the depressd serum inorganic phosphorus.'*' In one case of
phosphate diabetes the serum phospho-lipid fraction was increased twofold.' An answer
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to the significance of these observations may be found in the more complete analysis
of the various phosphorus containing fractions of the serum and red blood cefls
before and after treatment.
That sub-clinical exposure to toxic agents could cause phosphate diabetes is worthy
of consideration. Inhibition of tubular mechanisms is utilized in the action of certain
drugs such as benemid and sodium para-aminohippuric acid. Both of these substances
have been shown to have as one of their actions the reduced renal tubular reabsorption
of phosphorus.'"''•''5 In lead poisoning and in Wilson's disease hyperphosphaturia has
been reported,"'-"' possibly resulting from an inhibition of renal tubular enzyme systems
by excessive concentrations of lead and copper respectively. Of even possible greater
significance is the production in rats by Harrison of excessive excretion of urinary
phosphorus by the injection of maleate." In this instance, glucosuria and amino-aciduria
also occurred. The possibility that in phosphate diabetes some unknown toxic substances
impairing the renal tubular transport mechanisms of phosphorus and causing hyperphosphaturia has not been excluded. The high family incidence might then be explained
on the basis of a common exposure. There is evidence that certain other renal tubular
defects such as idiopathic hypercalciuria results from renal tubular damage due to
pyelonephritis."' There is no evidence to support such a mechanism in phosphate diabetes.
SUMMARY
A cflnical review of the disease entity, phosphate diabetes, based on the study of
150 cases gathered from the world literature is presented. The postulate that the
entity is due to an intrinsic resistance to vitamin D is critically reviewed. Evidence is
discussed that would preferentially designate the condition to result from a primary
urinary phosphorus loss, followed in turn by hypophosphatemia and osteomalacia.
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Table 1 — Adult Cases of Phosphate Diabetes
AGE SEX AGE
OF
AT PRESENTING
ONSET
DIAG- SYMPTOMS
(YRS)
NOSIS

INITIAL
LOSS
PSEUDO
OF
(MGM.%)
FRACTURES
HT.
CALCIUM

(MGM.9c)
PHOS.

DURING
ALK. VITAMIN D TREATMENT (MGM.%) A L K .
PHOS. PER DAY
(MGM.%)
PHOS.
PHOS.
Ca

Pain in
Linder and Vadas.'^ tibia. Later
in knees
15
M
19 and entire
skeleton.

McCance."
15

F

Salvesen."
35
F

20

Rolling
gait. Bone pain
Weakness.

39

Bone pain.
Advancing
weakness.

Elliotts'
M
29

+

+

10.5

9.3

Lower back
pain. Later
in knees and
ankles.

Salvesen."
54
M
Smeenk."
'.'Child- M
hood
? 53

Cod Liver
Oil

57

33

Lower back
pain.

H).:
9.2

Stiff back.
Later pain and
muscular weakness in lower
extremities.

10.6

2.5

23
(N3-13)

500,000
lU

1.6

6.68
U.

125,000
lU

1.4

2.2
Bod.

210,000
lU
70,000
lU

1.8
2.2

2- K,A

11.2
Bod.

11.0

Wassermann in
CSF positive, in
serum negative.
Enlarged parathyroids 850 mgm.

11.4

10.8

4.5

11.9

3.9

COMMENTS

Parathyroid ex10.5 ploration. TumorBod. like degeneration
of osteoid tissue
2.75 moved from right
Bod. removed from right
femur.

2.5

6.68

Parathyroids
macroscopically
hypertrophied.
microscopically
normal.

8.9
10.2

1.8

3.3

Muscle rigidity.

600,000
lU

10

3.8

500,000
lU

14.2

?4

lOKA Neurofibromatosis.

CSF albumin
increased to 220
mgm.%.

Table 1 — continued
AGE
SEX A G E
OF
A T PRESENTING
ONSET
D I A G - SYMPTOMS
NOSIS

Segar, et a l . "
20
M

24

LOSS
OF
HT.

Backache
after a
fall. Later
pain R. foot
and leg.

PSEUDO
FRACTURES

INITIAL
(MGM.%)
CALCIUM

+

11.0

(MGM.%)
PHOS.

DURING
ALK. VITAMIN D TREATMENT
PHOS. PER D A Y
(MGM.%)
Ca

8
Bod.

100,000
USP

12.8

250,000

i;

(MGM.%) ALK.
PHOS.
PHOS.

COMMENTS

History of syphilis

2.4

Nordin & Frazer^'
"Child- F
33
hood"
(?20)

Bedridden
dwarf.

+

+

Dent."
40

Bone pain.

+

...

+

-r-

Norm.

Low

+

10.6

0,7

over
25 Bod.

200,000

N

2.4

Lowered.

(Intermittent minimal glycosuria).
Parathyroids showed
areas of hyperplasia.

2.0

6.6
Bod.

100,000
USP
180,000
USP

10.0
10.5

2.2
2,6

4
Bod.
5
Bod.

Parathyroidectomy.
Showed some areas
of Parathyroid
hyperplasia.

3.1

8.0
Bod.

(Large
dose)

5.6

1.4
Bod.

Neurofibromatosis.

F

52

Swann."
58

Henneman.2^
19
F

Frame, Smith.'
30
F

Lievre, et al."'
37
M

33

35

41

Pain in
feet. Increasing
weakness. Later
generalized
bone pain.

&

Neurofibromatosis

ii.i)

1,000,000
lU

Low

Bone pain
first in
back and leg.

+

+

11.0

Back pain.
Then lawer
limbs incapacitated.

+

+

'».l

Neurofibromatosis

Neurofibromatosis

